Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 605 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Food for Thought: A Fresh Perspective on Nutrition February 5, 2021 Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... April 11, 2022 This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... March 22, 2019 New Research in Treating Metastatic Breast Cancer, Preventing Breast Cancer, and... February 7, 2023 Load more HOT NEWS Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma Study Shows CAR T-Cell Therapy Is Effective at Putting Childhood Leukemia... Using Technology to Find Cancers Early and Exercise Improves Sexual Health... Biomedical Engineering Student Invents Device for At-Home Breast Cancer Screening
